Over the last several decades, advances in non-Hodgkin lymphoma (NHL) management have improved survival; however, relapse and the emergence of treatment-resistant NHL following standard therapy remain ongoing treatment challenges. With conventional therapy for B-cell NHL, response rates are suboptimal and many patients relapse, highlighting the need for novel treatments that address the risk of disease progression. Recently, several novel therapies—including small-molecule inhibitors of the B-cell receptor pathway and next-generation monoclonal antibody therapies—have emerged or advanced in clinical trials. These agents offer the potential to dramatically improve outcomes in some treatment-resistant patients.
This activity has been developed to help advanced-practice oncology professionals stay current on the newest targeted NHL therapies and the best strategies for their effective use, particularly in the management of patients with multidrug-resistant and relapsing NHL. Additionally, this activity reviews current best practices for detecting variations in the natural history of NHL over time with the goal of improving long-term outcomes.
This activity has been designed to meet the educational needs of oncology nurse practitioners, physician assistants, pharmacists, nurse specialists, and other health care providers (HCPs) involved in the management of oncology patients.
Upon completion of this activity, participants should be able to:
Activity Launch Date - 4/8/2019
Expiration Date - 4/8/2020
Supporter Acknowledgment Statement
This activity is supported by an educational grant from Celgene Corporation, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
“Treating B-Cell Lymphomas: Novel Agents and the Evolving State of Practice" was planned and implemented in partnership between HorizonCME and RedMedEd.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information presented in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of an HCP regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Washington State Pharmacy Association, Horizon CME, RedMedEd, Celgene Corporation, Pharmacyclics LLC, an AbbVie Company, or Janssen Biotech, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Statement of Independence
Horizon CME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Horizon CME to develop and present educational activities that are timely, fair balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome comments about how to better serve your needs.
Copyright © 2019 - All rights reserved. This CME-certified program is held as copyrighted by Washington State Pharmacy Association, Horizon CME, and RedMedEd. Through this notice, Washington State Pharmacy Association, Horizon CME, and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.